Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

Fig. 1

The Changes in target lesions size. A Changes of target lesion size at different evaluation time points compared to the baseline for the patients whose efficacy data were available (N = 109). B Best percentage change in target lesion size from baseline based on IRC assessment per RECIST v1.1 for the patients whose efficacy data were available (N = 109)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us